首页 > 最新文献

Drugs under experimental and clinical research最新文献

英文 中文
Bioavailability of tyrosol, an antioxidant phenolic compound present in wine and olive oil, in humans. 酪醇,一种存在于葡萄酒和橄榄油中的抗氧化酚类化合物,在人体中的生物利用度。
M I Covas, E Miró-Casas, M Fitó, M Farré-Albadalejo, E Gimeno, J Marrugat, R De La Torre

Tyrosol is a phenolic compound present in two of the traditional components of the Mediterranean diet: wine and virgin olive oil. The presence of tyrosol has been described in red and white wines. Tyrosol is also present in vermouth and beer. Tyrosol has been shown to be able to exert antioxidant activity in in vitro studies. Oxidation of low-density lipoprotein (LDL) appears to occur predominantly in arterial intima in microdomains sequestered from antioxidants of plasma. The antioxidant content of the LDL particle is critical for its protection. Thus, phenolics, which are able to bind LDL, could be effective in preventing lipid peroxidation and atherosclerotic processes. The ability of tyrosol to bind human LDL has been reported. We have demonstrated the bioavailability of tyrosol in humans from virgin olive oil in its natural form. Urinary tyrosol increased, reaching a peak at 0-4 h after virgin olive oil administration. Men and women showed a different pattern of urinary excretion of tyrosol. Moreover, tyrosol is absorbed in a dose-dependent manner after sustained and moderate doses of virgin olive oil. In summary, our results suggest that tyrosol from wine or virgin olive oil could exert beneficial effects on human health in vivo if its biological properties are confirmed in in vivo studies.

酪醇是一种酚类化合物,存在于地中海饮食的两种传统成分:葡萄酒和初榨橄榄油中。红葡萄酒和白葡萄酒中都有酪醇的存在。苦艾酒和啤酒中也含有酪醇。在体外研究中,酪醇已被证明能够发挥抗氧化活性。低密度脂蛋白(LDL)的氧化似乎主要发生在与血浆抗氧化剂隔离的动脉内膜微域中。低密度脂蛋白颗粒的抗氧化剂含量对其保护至关重要。因此,能够结合LDL的酚类物质可以有效地防止脂质过氧化和动脉粥样硬化过程。已报道酪醇结合人LDL的能力。我们已经证明了天然形式的初榨橄榄油对人体的生物利用度。尿酪醇增加,在初榨橄榄油后0-4小时达到峰值。男性和女性的酪醇尿排泄模式不同。此外,在持续和中等剂量的初榨橄榄油后,酪醇以剂量依赖的方式被吸收。总之,我们的研究结果表明,如果从葡萄酒或初榨橄榄油中提取的酪醇的生物学特性得到体内研究的证实,它可能对人体健康有有益的影响。
{"title":"Bioavailability of tyrosol, an antioxidant phenolic compound present in wine and olive oil, in humans.","authors":"M I Covas,&nbsp;E Miró-Casas,&nbsp;M Fitó,&nbsp;M Farré-Albadalejo,&nbsp;E Gimeno,&nbsp;J Marrugat,&nbsp;R De La Torre","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Tyrosol is a phenolic compound present in two of the traditional components of the Mediterranean diet: wine and virgin olive oil. The presence of tyrosol has been described in red and white wines. Tyrosol is also present in vermouth and beer. Tyrosol has been shown to be able to exert antioxidant activity in in vitro studies. Oxidation of low-density lipoprotein (LDL) appears to occur predominantly in arterial intima in microdomains sequestered from antioxidants of plasma. The antioxidant content of the LDL particle is critical for its protection. Thus, phenolics, which are able to bind LDL, could be effective in preventing lipid peroxidation and atherosclerotic processes. The ability of tyrosol to bind human LDL has been reported. We have demonstrated the bioavailability of tyrosol in humans from virgin olive oil in its natural form. Urinary tyrosol increased, reaching a peak at 0-4 h after virgin olive oil administration. Men and women showed a different pattern of urinary excretion of tyrosol. Moreover, tyrosol is absorbed in a dose-dependent manner after sustained and moderate doses of virgin olive oil. In summary, our results suggest that tyrosol from wine or virgin olive oil could exert beneficial effects on human health in vivo if its biological properties are confirmed in in vivo studies.</p>","PeriodicalId":11336,"journal":{"name":"Drugs under experimental and clinical research","volume":"29 5-6","pages":"203-6"},"PeriodicalIF":0.0,"publicationDate":"2003-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"24510942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Postprandial effects of wine consumption on lipids and oxidative stress biomarkers. 餐后葡萄酒消费对脂质和氧化应激生物标志物的影响。
M I Covas, V Konstantinidou, E Mysytaki, M Fitó, T Weinbrenner, R De La Torre, M Farré-Albadalejo, R Lamuela-Raventós

Postprandial lipemia has been recognized as a risk factor for atherosclerosis development. Consuming meals with suitable sources of antioxidants such as red wine reduces postprandial oxidative stress. However, information about the postprandial effects of wine ingestion outside meals on lipids and on in vivo low-density lipoprotein (LDL) oxidation in humans is scarce. The aim of this study was to investigate postprandial changes in lipids and in vivo LDL oxidation after moderate (250 ml) red wine ingestion, before and after sustained wine consumption of 250 ml/day for 4 days. After 4 days of sustained wine consumption a decrease in the LDL/high-density lipoprotein cholesterol ratio was observed after wine ingestion (p = 0.026). On day 4, a decrease in oxidized LDL levels and an increase in the antioxidant enzyme glutathione peroxidase activity (p = 0.025) were observed after wine ingestion. Our results show that consumption of red wine at moderate doses outside meals does not promote oxidative stress. Daily consumption of moderate doses of red wine can improve postprandial lipid profile and oxidative status when wine is ingested outside meals.

餐后血脂已被认为是动脉粥样硬化发展的危险因素。食用含有适当抗氧化剂来源的食物,如红酒,可以减少餐后氧化应激。然而,关于餐后饮用葡萄酒对人体内脂质和低密度脂蛋白(LDL)氧化的影响的信息很少。本研究的目的是研究中度(250毫升)红酒摄入后,持续饮用250毫升/天的红酒前后4天的餐后血脂和体内LDL氧化的变化。持续饮用葡萄酒4天后,观察到饮用葡萄酒后LDL/高密度脂蛋白胆固醇比率下降(p = 0.026)。第4天,饮酒后小鼠氧化LDL水平降低,抗氧化酶谷胱甘肽过氧化物酶活性升高(p = 0.025)。我们的研究结果表明,在餐外适量饮用红酒不会促进氧化应激。每天适量饮用红酒可以改善餐后血脂和氧化状态。
{"title":"Postprandial effects of wine consumption on lipids and oxidative stress biomarkers.","authors":"M I Covas,&nbsp;V Konstantinidou,&nbsp;E Mysytaki,&nbsp;M Fitó,&nbsp;T Weinbrenner,&nbsp;R De La Torre,&nbsp;M Farré-Albadalejo,&nbsp;R Lamuela-Raventós","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Postprandial lipemia has been recognized as a risk factor for atherosclerosis development. Consuming meals with suitable sources of antioxidants such as red wine reduces postprandial oxidative stress. However, information about the postprandial effects of wine ingestion outside meals on lipids and on in vivo low-density lipoprotein (LDL) oxidation in humans is scarce. The aim of this study was to investigate postprandial changes in lipids and in vivo LDL oxidation after moderate (250 ml) red wine ingestion, before and after sustained wine consumption of 250 ml/day for 4 days. After 4 days of sustained wine consumption a decrease in the LDL/high-density lipoprotein cholesterol ratio was observed after wine ingestion (p = 0.026). On day 4, a decrease in oxidized LDL levels and an increase in the antioxidant enzyme glutathione peroxidase activity (p = 0.025) were observed after wine ingestion. Our results show that consumption of red wine at moderate doses outside meals does not promote oxidative stress. Daily consumption of moderate doses of red wine can improve postprandial lipid profile and oxidative status when wine is ingested outside meals.</p>","PeriodicalId":11336,"journal":{"name":"Drugs under experimental and clinical research","volume":"29 5-6","pages":"217-23"},"PeriodicalIF":0.0,"publicationDate":"2003-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"24510944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
New perspectives of research on wine and health. Proceedings of an international congress on wine and health. May 8-11, 2003. Marsala, Italy. 葡萄酒与健康研究的新视角。葡萄酒与健康国际会议论文集。2003年5月8日至11日。马沙拉白葡萄酒,意大利。
{"title":"New perspectives of research on wine and health. Proceedings of an international congress on wine and health. May 8-11, 2003. Marsala, Italy.","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":11336,"journal":{"name":"Drugs under experimental and clinical research","volume":" ","pages":"169-286"},"PeriodicalIF":0.0,"publicationDate":"2003-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"24909789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Potent in vivo antineoplastic activity of MCR peptides MCR-4 and MCR-14 against chemotherapy-resistant human small cell lung cancer. MCR肽MCR-4和MCR-14对化疗耐药人小细胞肺癌的体内有效抗肿瘤活性
R T Radulescu, G Jaques

Previous studies have shown that MCR peptides possessing the retinoblastoma protein (RB) fragment LFYKKV as the active site are able to inhibit the proliferation of human non-small cell lung cancer (NSCLC) cells in vitro and in vivo. The goal of the present study was to test these compounds against human small cell lung cancer (SCLC) in vivo since this tumor is notoriously resistant to conventional therapy or, respectively, is characterized by rapid relapse after initially successful treatment. We herein report that the MCR peptides MCR-4 and MCR-14 display potent antiproliferative activity against RB-negative H82 SCLC xenograft tumors in nude mice, whereas the chemotherapeutic agent VP-16 tested in parallel in a clinically relevant dose had no anti-tumor effect. These encouraging results warrant accelerating the introduction of MCR peptides into clinical trials in patients with RB-negative tumors such as SCLC in the near future.

既往研究表明,以视网膜母细胞瘤蛋白(retinoblastoma protein, RB)片段LFYKKV为活性位点的MCR肽在体外和体内均能抑制人非小细胞肺癌(NSCLC)细胞的增殖。本研究的目的是在体内测试这些化合物对人小细胞肺癌(SCLC)的治疗作用,因为这种肿瘤对常规治疗是出了名的耐药,或者在最初成功治疗后迅速复发。我们在此报道了MCR肽MCR-4和MCR-14在裸鼠中对rh阴性H82 SCLC异种移植肿瘤显示出有效的抗增殖活性,而在临床相关剂量下并行测试的化疗药物VP-16没有抗肿瘤作用。这些令人鼓舞的结果保证在不久的将来加速将MCR肽引入rb阴性肿瘤(如SCLC)患者的临床试验。
{"title":"Potent in vivo antineoplastic activity of MCR peptides MCR-4 and MCR-14 against chemotherapy-resistant human small cell lung cancer.","authors":"R T Radulescu,&nbsp;G Jaques","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Previous studies have shown that MCR peptides possessing the retinoblastoma protein (RB) fragment LFYKKV as the active site are able to inhibit the proliferation of human non-small cell lung cancer (NSCLC) cells in vitro and in vivo. The goal of the present study was to test these compounds against human small cell lung cancer (SCLC) in vivo since this tumor is notoriously resistant to conventional therapy or, respectively, is characterized by rapid relapse after initially successful treatment. We herein report that the MCR peptides MCR-4 and MCR-14 display potent antiproliferative activity against RB-negative H82 SCLC xenograft tumors in nude mice, whereas the chemotherapeutic agent VP-16 tested in parallel in a clinically relevant dose had no anti-tumor effect. These encouraging results warrant accelerating the introduction of MCR peptides into clinical trials in patients with RB-negative tumors such as SCLC in the near future.</p>","PeriodicalId":11336,"journal":{"name":"Drugs under experimental and clinical research","volume":"29 2","pages":"69-74"},"PeriodicalIF":0.0,"publicationDate":"2003-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"22558113","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Double-blind, randomized, controlled study on the efficacy and safety of a novel diclofenac epolamine gel formulated with lecithin for the treatment of sprains, strains and contusions. 一种新型卵磷脂双氯芬酸依泊拉胺凝胶治疗扭伤、拉伤和挫伤的疗效和安全性的双盲、随机、对照研究。
P Mahler, F Mahler, H Duruz, M Ramazzina, V Liguori, G Mautone

To evaluate the efficacy of the new diclofenac-N-(2-hydroxyethyl)-pyrrolidine gel formulated with lecithin (DHEP lecithin) compared with diclofenac-N-(2-hydroxyethyl)-pyrrolidine gel (DHEP gel) without lecithin in mild-to-moderate posttraumatic injuries (grade 1 ankle, knee and muscle injuries), a multicenter, double-blind, controlled study was carried out. A total of 100 patients were enrolled and randomly assigned to either DHEP lecithin (n = 52) or DHEP gel (n = 48) treatment. All patients concluded the treatment period except for five, who did not turn up to their respective investigational sites for the follow-up visits. According to an intention-to-treat approach, they were all included in the statistical analysis. As for the efficacy and safety analysis, the primary variable was "pain on movement" as measured by a Huskisson visual analog scale. During the first 3 days of treatment each group recorded a significant within-group decrease, but patients treated with DHEP lecithin showed a decrease in absolute value that was statistically greater than that obtained with DHEP gel (p = 0.025). At the end of the treatment period (day 10) the difference between groups was still statistically significant (p = 0.036). The statistical analysis of the secondary efficacy variables showed significant results in favor of DHEP lecithin treatment. These were superimposable on the results found for the primary variable. The global efficacy and tolerability judgments, reported either by patient or by physician, showed no statistical difference between treatment groups. Due to the presence of lecithin in the new gel formulation, DHEP lecithin showed a faster and significantly more marked therapeutic effect compared with that of DHEP gel.

为了评价新型双氯芬酸- n -(2-羟乙基)-吡咯烷凝胶(DHEP卵磷脂)与不含卵磷脂的双氯芬酸- n -(2-羟乙基)-吡咯烷凝胶(DHEP凝胶)在轻中度创伤后损伤(1级踝关节、膝关节和肌肉损伤)中的疗效,进行了一项多中心、双盲、对照研究。共有100名患者被纳入研究,随机分配到DHEP卵磷脂(n = 52)或DHEP凝胶(n = 48)治疗组。所有患者均结束了治疗期,只有5名患者没有到各自的研究地点进行随访。根据意向治疗方法,他们都被纳入统计分析。至于疗效和安全性分析,主要变量是“运动疼痛”,由Huskisson视觉模拟量表测量。在治疗的前3天,各组均有显著的组内下降,但DHEP卵磷脂组患者的绝对值下降幅度大于DHEP凝胶组(p = 0.025)。在治疗期结束时(第10天),组间差异仍有统计学意义(p = 0.036)。对次要疗效变量的统计分析显示,DHEP卵磷脂治疗效果显著。这些结果与主要变量的结果是重叠的。由患者或医生报告的总体疗效和耐受性判断在治疗组之间没有统计学差异。由于新凝胶配方中含有卵磷脂,与脱氢hep凝胶相比,脱氢hep卵磷脂的治疗效果更快、更显著。
{"title":"Double-blind, randomized, controlled study on the efficacy and safety of a novel diclofenac epolamine gel formulated with lecithin for the treatment of sprains, strains and contusions.","authors":"P Mahler,&nbsp;F Mahler,&nbsp;H Duruz,&nbsp;M Ramazzina,&nbsp;V Liguori,&nbsp;G Mautone","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>To evaluate the efficacy of the new diclofenac-N-(2-hydroxyethyl)-pyrrolidine gel formulated with lecithin (DHEP lecithin) compared with diclofenac-N-(2-hydroxyethyl)-pyrrolidine gel (DHEP gel) without lecithin in mild-to-moderate posttraumatic injuries (grade 1 ankle, knee and muscle injuries), a multicenter, double-blind, controlled study was carried out. A total of 100 patients were enrolled and randomly assigned to either DHEP lecithin (n = 52) or DHEP gel (n = 48) treatment. All patients concluded the treatment period except for five, who did not turn up to their respective investigational sites for the follow-up visits. According to an intention-to-treat approach, they were all included in the statistical analysis. As for the efficacy and safety analysis, the primary variable was \"pain on movement\" as measured by a Huskisson visual analog scale. During the first 3 days of treatment each group recorded a significant within-group decrease, but patients treated with DHEP lecithin showed a decrease in absolute value that was statistically greater than that obtained with DHEP gel (p = 0.025). At the end of the treatment period (day 10) the difference between groups was still statistically significant (p = 0.036). The statistical analysis of the secondary efficacy variables showed significant results in favor of DHEP lecithin treatment. These were superimposable on the results found for the primary variable. The global efficacy and tolerability judgments, reported either by patient or by physician, showed no statistical difference between treatment groups. Due to the presence of lecithin in the new gel formulation, DHEP lecithin showed a faster and significantly more marked therapeutic effect compared with that of DHEP gel.</p>","PeriodicalId":11336,"journal":{"name":"Drugs under experimental and clinical research","volume":"29 1","pages":"45-52"},"PeriodicalIF":0.0,"publicationDate":"2003-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"22486428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mast cell stabilization, lipoxygenase inhibition, hyaluronidase inhibition, antihistaminic and antispasmodic activities of Aller-7, a novel botanical formulation for allergic rhinitis. 一种治疗变应性鼻炎的新型植物制剂Aller-7具有稳定肥大细胞、抑制脂氧合酶、抑制透明质酸酶、抗组胺和抗痉挛活性。
A Amit, V S Saxena, N Pratibha, P D'Souza, M Bagchi, D Bagchi, S J Stohs

Allergic rhinitis, also known as hay fever, rose fever or summer catarrh, is a major challenge to health professionals. A large number of the world's population, including approximately 40 million Americans, suffers from allergic rhinitis. A novel, botanical formulation (Aller-7) has been developed for the treatment of allergic rhinitis using a combination of extracts from seven medicinal plants, including Phyllanthus emblica, Terminalia chebula, T. bellerica, Albizia lebbeck, Piper nigrum, Zingiber officinale and P. longum, which have a proven history of efficacy and health benefits. The clinical manifestations of allergy are due to a number of mediators that are released from mast cells. The effect of Aller-7 on rat mesenteric mast cell degranulation was studied by incubating different concentrations of Aller-7 and challenging them with a degranulating agent, compound 48/80. The inhibitory activity of Aller-7 was determined against lipoxygenase and hyaluronidase, the key enzymes involved in the initiation and maintenance of inflammatory responses. Furthermore, most of these manifestations are due to histamine, which causes vasodilatation, increasing capillary permeability and leading to bronchoconstriction. Hence, the antihistaminic activity of Aller-7 was determined is isolated guinea pig ileum substrate using cetirizine as a positive control. The antispasmodic effect of Aller-7 on contractions of guinea pig tracheal chain was determined using papaverine and cetirizine as controls. Aller-7 exhibited potent activity in all these in vitro models tested, thus demonstrating the novel anti-allergic potential of Aller-7.

过敏性鼻炎,也被称为花粉热、玫瑰热或夏季黏膜炎,是卫生专业人员面临的主要挑战。世界上很多人,包括大约4000万美国人,都患有过敏性鼻炎。一种新型的植物制剂(Aller-7)已经被开发出来用于治疗过敏性鼻炎,它使用了七种药用植物的提取物的组合,包括Phyllanthus emblica, Terminalia chebula, T. bellerica, Albizia lebbeck, Piper nigrum, Zingiber officinale和P. longum,这些植物已经被证明具有疗效和健康益处。过敏的临床表现是由于肥大细胞释放了许多介质。通过培养不同浓度的Aller-7,并用复方48/80脱粒剂刺激它们,研究了Aller-7对大鼠肠系膜肥大细胞脱粒的影响。Aller-7对脂氧合酶和透明质酸酶的抑制活性测定,这两种酶参与炎症反应的启动和维持。此外,这些表现大多是由组胺引起的,组胺引起血管扩张,毛细血管通透性增加,导致支气管收缩。因此,以西替利嗪为阳性对照,测定了豚鼠回肠底物中Aller-7的抗组胺活性。以罂粟碱和西替利嗪为对照,观察Aller-7对豚鼠气管链收缩的抗痉挛作用。Aller-7在所有这些体外模型中都表现出强大的活性,从而证明了Aller-7具有新的抗过敏潜力。
{"title":"Mast cell stabilization, lipoxygenase inhibition, hyaluronidase inhibition, antihistaminic and antispasmodic activities of Aller-7, a novel botanical formulation for allergic rhinitis.","authors":"A Amit,&nbsp;V S Saxena,&nbsp;N Pratibha,&nbsp;P D'Souza,&nbsp;M Bagchi,&nbsp;D Bagchi,&nbsp;S J Stohs","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Allergic rhinitis, also known as hay fever, rose fever or summer catarrh, is a major challenge to health professionals. A large number of the world's population, including approximately 40 million Americans, suffers from allergic rhinitis. A novel, botanical formulation (Aller-7) has been developed for the treatment of allergic rhinitis using a combination of extracts from seven medicinal plants, including Phyllanthus emblica, Terminalia chebula, T. bellerica, Albizia lebbeck, Piper nigrum, Zingiber officinale and P. longum, which have a proven history of efficacy and health benefits. The clinical manifestations of allergy are due to a number of mediators that are released from mast cells. The effect of Aller-7 on rat mesenteric mast cell degranulation was studied by incubating different concentrations of Aller-7 and challenging them with a degranulating agent, compound 48/80. The inhibitory activity of Aller-7 was determined against lipoxygenase and hyaluronidase, the key enzymes involved in the initiation and maintenance of inflammatory responses. Furthermore, most of these manifestations are due to histamine, which causes vasodilatation, increasing capillary permeability and leading to bronchoconstriction. Hence, the antihistaminic activity of Aller-7 was determined is isolated guinea pig ileum substrate using cetirizine as a positive control. The antispasmodic effect of Aller-7 on contractions of guinea pig tracheal chain was determined using papaverine and cetirizine as controls. Aller-7 exhibited potent activity in all these in vitro models tested, thus demonstrating the novel anti-allergic potential of Aller-7.</p>","PeriodicalId":11336,"journal":{"name":"Drugs under experimental and clinical research","volume":"29 3","pages":"107-15"},"PeriodicalIF":0.0,"publicationDate":"2003-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"24152233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparative effect of clinidipine and quinapril on left ventricular mass in mild essential hypertension. 临床地平与喹普利对轻度原发性高血压患者左心室质量的影响比较。
K Sakata, H Yoshida, H Tamekiyo, K Obayashi, R Nawada, O Doi, N Mori

The aim of this study was to compare the regressive effect of clinidipine on left ventricular mass (LVM) with that of quinapril. Sixty patients with mild essential hypertension aged more than 39 years were randomly allocated to two groups to receive cilnidipine (10 mg; n = 30) or quinapril (10 mg; n = 30). The patients underwent echocardiography before and 12 months after drug treatment. Sixteen patients in each group underwent 123I-metaiodobenzylguanidine (MIBG) cardiac imaging before and 12 months after drug treatment. In both groups systolic and diastolic blood pressures significantly decreased to similar levels. In the clinidipine group, both end-diastolic and end-systolic diameters and posterior wall thickness significantly decreased, while only end-systolic diameter significantly decreased in the quinapril group. However, LVM (206 +/- 36 g to 189 +/- 40 g, p < 0.02 for the quinapril group, 195 +/- 60 g to 171 +/- 48 g, p < 0.004 for the clinidipine group) and the LVM index (127 +/- 20 g/m2, to 116 +/- 20 g/m2, p < 0.02 for the quinapril group, 121 +/- 32 g/m2 to 106 +/- 24 g/m2 p < 0.003 for the clinidipine group) significantly decreased in both groups. Regarding MIBG imaging, in the cilnidipine group, the heart-to-mediastinum ratio significantly increased (p < 0.02) and the washout rate significantly decreased (p < 0.02) after drug treatment. In contrast, there were no significant changes in MIBG parameters in the quinapril group. Clinidipine produced a greater decrease in LVM in essential hypertension than quinapril, probably due to the long-term suppression of the cardiac sympathetic nervous system. Clinidipine is useful for hypertensive patients with left ventricular hypertrophy and may improve their prognosis.

本研究的目的是比较临床地平与喹普利对左心室质量(LVM)的消退作用。60例年龄大于39岁的轻度原发性高血压患者随机分为两组,接受西尼地平治疗(10mg;N = 30)或喹普利(10 mg;N = 30)。患者在药物治疗前和治疗后12个月分别行超声心动图检查。每组16例患者在用药前和用药后12个月行123i -甲氧十二苄基胍(MIBG)心脏显像。两组患者的收缩压和舒张压均降至相似水平。临床地平组舒张末期和收缩末期直径及后壁厚度均显著降低,而喹普利组仅收缩末期直径显著降低。然而,LVM (206 +/- 36 g至189 +/- 40 g, quinapril组p < 0.02, 195 +/- 60 g至171 +/- 48 g, clininidipine组p < 0.004)和LVM指数(127 +/- 20 g/m2,至116 +/- 20 g/m2, quinapril组p < 0.02, 121 +/- 32 g/m2至106 +/- 24 g/m2, clininidipine组p < 0.003)在两组均显著降低。在MIBG成像方面,西尼地平组药物治疗后心脏与纵隔比值显著升高(p < 0.02),洗脱率显著降低(p < 0.02)。相比之下,喹诺普利组的MIBG参数没有明显变化。与喹奈普利相比,克利地平对原发性高血压患者LVM的降低作用更大,这可能是由于长期抑制心脏交感神经系统所致。克利地平对左心室肥厚的高血压患者有效,可改善其预后。
{"title":"Comparative effect of clinidipine and quinapril on left ventricular mass in mild essential hypertension.","authors":"K Sakata,&nbsp;H Yoshida,&nbsp;H Tamekiyo,&nbsp;K Obayashi,&nbsp;R Nawada,&nbsp;O Doi,&nbsp;N Mori","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The aim of this study was to compare the regressive effect of clinidipine on left ventricular mass (LVM) with that of quinapril. Sixty patients with mild essential hypertension aged more than 39 years were randomly allocated to two groups to receive cilnidipine (10 mg; n = 30) or quinapril (10 mg; n = 30). The patients underwent echocardiography before and 12 months after drug treatment. Sixteen patients in each group underwent 123I-metaiodobenzylguanidine (MIBG) cardiac imaging before and 12 months after drug treatment. In both groups systolic and diastolic blood pressures significantly decreased to similar levels. In the clinidipine group, both end-diastolic and end-systolic diameters and posterior wall thickness significantly decreased, while only end-systolic diameter significantly decreased in the quinapril group. However, LVM (206 +/- 36 g to 189 +/- 40 g, p < 0.02 for the quinapril group, 195 +/- 60 g to 171 +/- 48 g, p < 0.004 for the clinidipine group) and the LVM index (127 +/- 20 g/m2, to 116 +/- 20 g/m2, p < 0.02 for the quinapril group, 121 +/- 32 g/m2 to 106 +/- 24 g/m2 p < 0.003 for the clinidipine group) significantly decreased in both groups. Regarding MIBG imaging, in the cilnidipine group, the heart-to-mediastinum ratio significantly increased (p < 0.02) and the washout rate significantly decreased (p < 0.02) after drug treatment. In contrast, there were no significant changes in MIBG parameters in the quinapril group. Clinidipine produced a greater decrease in LVM in essential hypertension than quinapril, probably due to the long-term suppression of the cardiac sympathetic nervous system. Clinidipine is useful for hypertensive patients with left ventricular hypertrophy and may improve their prognosis.</p>","PeriodicalId":11336,"journal":{"name":"Drugs under experimental and clinical research","volume":"29 3","pages":"117-23"},"PeriodicalIF":0.0,"publicationDate":"2003-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"24152234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Overview of epidemiological studies on wine, health and mortality. 葡萄酒、健康和死亡率的流行病学研究综述。
J C Ruf

Numerous epidemiological studies have observed that moderate intake of alcohol including wine is associated with a lower risk of cardiovascular disease (CVD). However, according to several authors, moderate consumption of wine is more beneficial than that of beer or spirits. Some studies have shown that moderate consumption of wine can lower mortality from CVD and other causes. The link between drinking wine and total mortality risk (all causes combined) has been studied. The results of various prospective population studies show that intake of beer and spirits from abstention to light to moderate daily intake did not influence mortality, while wine seems to have a beneficial effect on all causes of mortality. Other studies have reached the same conclusion. In general, several authors have reported that in subjects consuming wine in moderation the risk of mortality from all causes is 20-30% lower than in abstainers. Grape wine appears to be the main alcoholic beverage that contains antioxidant phenolic substances known to inhibit oxidation of low-density lipoprotein and affect hemostasis and carcinogenesis. In conclusion, there are differences in the effects of wine, beer and spirits on health. These differences may not be significant in coronary heart disease. Only moderate wine consumption appears to have a beneficial effect on several types of cancer and on total mortality.

大量流行病学研究发现,适量摄入酒精(包括葡萄酒)与心血管疾病(CVD)风险降低有关。然而,根据几位作者的说法,适量饮用葡萄酒比啤酒或烈酒更有益。一些研究表明,适度饮用葡萄酒可以降低心血管疾病和其他原因的死亡率。饮用葡萄酒与总死亡风险(所有原因加起来)之间的联系已经被研究过。各种前瞻性人口研究的结果表明,从不喝到每天少量到适量的啤酒和烈酒的摄入对死亡率没有影响,而葡萄酒似乎对所有死亡原因都有有益的影响。其他研究也得出了同样的结论。一般来说,几位作者报告说,适度饮酒的人死于各种原因的风险比不喝酒的人低20-30%。葡萄酒似乎是含有抗氧化酚类物质的主要酒精饮料,已知酚类物质可以抑制低密度脂蛋白的氧化,影响止血和致癌。总之,葡萄酒、啤酒和烈酒对健康的影响是不同的。这些差异在冠心病中可能不显著。只有适度的葡萄酒消费似乎对几种癌症和总死亡率有有益的影响。
{"title":"Overview of epidemiological studies on wine, health and mortality.","authors":"J C Ruf","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Numerous epidemiological studies have observed that moderate intake of alcohol including wine is associated with a lower risk of cardiovascular disease (CVD). However, according to several authors, moderate consumption of wine is more beneficial than that of beer or spirits. Some studies have shown that moderate consumption of wine can lower mortality from CVD and other causes. The link between drinking wine and total mortality risk (all causes combined) has been studied. The results of various prospective population studies show that intake of beer and spirits from abstention to light to moderate daily intake did not influence mortality, while wine seems to have a beneficial effect on all causes of mortality. Other studies have reached the same conclusion. In general, several authors have reported that in subjects consuming wine in moderation the risk of mortality from all causes is 20-30% lower than in abstainers. Grape wine appears to be the main alcoholic beverage that contains antioxidant phenolic substances known to inhibit oxidation of low-density lipoprotein and affect hemostasis and carcinogenesis. In conclusion, there are differences in the effects of wine, beer and spirits on health. These differences may not be significant in coronary heart disease. Only moderate wine consumption appears to have a beneficial effect on several types of cancer and on total mortality.</p>","PeriodicalId":11336,"journal":{"name":"Drugs under experimental and clinical research","volume":"29 5-6","pages":"173-9"},"PeriodicalIF":0.0,"publicationDate":"2003-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"24510939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison of chloroxylenol 0.5% plus salicylic acid 2% cream and benzoyl peroxide 5% gel in the treatment of acne vulgaris: a randomized double-blind study. 0.5%氯二醇加2%水杨酸乳膏和5%过氧化苯甲酰凝胶治疗寻常性痤疮的比较:一项随机双盲研究。
F Boutli, M Zioga, T Koussidou, D Ioannides, O Mourellou

A 12-week double-blind randomized study was performed to compare benzoyl peroxide 5% (BP) gel and chloroxylenol 0.5% plus salicylic acid 2% (PCMX + SA) cream (Nisal cream) for efficacy and adverse reactions. Thirty-seven volunteers participated in the study, 19 in the BP group and 18 in the PCMX + SA group. The patients applied the medication twice daily to the entire face. Clinical evaluation and lesion counts were obtained at 0, 3, 6, 9 and 12 weeks. At week 12 both groups showed a marked improvement in both inflammatory and noninflammatory lesions (60% and 54% for the BP group and 62% and 56% for and 56% for the PCMX + SA group, respectively). Although PCMX + SA showed a slightly stronger keratolytic effect throughout the study period, there was no statistically significant difference in the reduction of the papulopustules or comedones between the two groups. Adverse effects such as erythema and photosensitivity were significantly fewer in the PCMX + SA group at week 12 (p = 0.0002 and p = 0.05, respectively). These results suggest that PCMX + SA cream is as effective as BP gel in the treatment of papulopustular and comedonal acne and that it is better tolerated.

通过为期12周的随机双盲研究,比较5%过氧化苯甲酰(BP)凝胶和0.5%氯二醇加2%水杨酸(PCMX + SA)乳膏(Nisal乳膏)的疗效和不良反应。37名志愿者参加了这项研究,BP组19人,PCMX + SA组18人。病人们每天两次把这种药涂在整个脸上。在0、3、6、9和12周获得临床评价和病变计数。在第12周,两组的炎症性和非炎症性病变均有显著改善(BP组分别为60%和54%,PCMX + SA组分别为62%和56%和56%)。虽然PCMX + SA在整个研究期间的溶角作用稍强,但两组在丘疹或粉刺的减少上无统计学差异。第12周,PCMX + SA组的红斑、光敏性等不良反应明显减少(p = 0.0002和p = 0.05)。上述结果提示PCMX + SA乳膏治疗丘疹性痤疮和喜剧性痤疮的效果与BP凝胶相当,且耐受性更好。
{"title":"Comparison of chloroxylenol 0.5% plus salicylic acid 2% cream and benzoyl peroxide 5% gel in the treatment of acne vulgaris: a randomized double-blind study.","authors":"F Boutli,&nbsp;M Zioga,&nbsp;T Koussidou,&nbsp;D Ioannides,&nbsp;O Mourellou","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>A 12-week double-blind randomized study was performed to compare benzoyl peroxide 5% (BP) gel and chloroxylenol 0.5% plus salicylic acid 2% (PCMX + SA) cream (Nisal cream) for efficacy and adverse reactions. Thirty-seven volunteers participated in the study, 19 in the BP group and 18 in the PCMX + SA group. The patients applied the medication twice daily to the entire face. Clinical evaluation and lesion counts were obtained at 0, 3, 6, 9 and 12 weeks. At week 12 both groups showed a marked improvement in both inflammatory and noninflammatory lesions (60% and 54% for the BP group and 62% and 56% for and 56% for the PCMX + SA group, respectively). Although PCMX + SA showed a slightly stronger keratolytic effect throughout the study period, there was no statistically significant difference in the reduction of the papulopustules or comedones between the two groups. Adverse effects such as erythema and photosensitivity were significantly fewer in the PCMX + SA group at week 12 (p = 0.0002 and p = 0.05, respectively). These results suggest that PCMX + SA cream is as effective as BP gel in the treatment of papulopustular and comedonal acne and that it is better tolerated.</p>","PeriodicalId":11336,"journal":{"name":"Drugs under experimental and clinical research","volume":"29 3","pages":"101-5"},"PeriodicalIF":0.0,"publicationDate":"2003-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"24152232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Neutral sphingomyelinase inhibitor C11AG prevents lipopolysaccharide-induced macrophage activation. 中性鞘磷脂酶抑制剂C11AG阻止脂多糖诱导的巨噬细胞活化。
E Amtmann, W Baader, M Zöller

Stimulation of macrophages by lipopolysaccharide (LPS) leads to the synthesis of proinflammatory cytokines and nitric oxide (NO) and, as a consequence, to endotoxic shock. We provide evidence that LPS stimulates the activity of a membrane-associated neutral sphingomyelinase (nSMase) and that this activity is mandatory for the liberation of nuclear factor-kappa B (NF kappa B) and the induction of inducible NO-synthase (iNOS). With the aid of a newly developed, selective inhibitor of nSMase, C11AG, we could distinguish between nSMase-dependent and -independent LPS-induced signals. C11AG blocked LPS-stimulated sphingomyelin degradation and NF kappa B activation without interfering with p42 tyrosine phosphorylation. Concomitantly, the expression of iNOS was found to be reduced both in mononuclear cells and in murine endotoxemia. Therefore, specific inhibitors of nSMase may define a new class of antiinflammatory substances.

脂多糖(LPS)刺激巨噬细胞导致促炎细胞因子和一氧化氮(NO)的合成,从而导致内源性休克。我们提供的证据表明,LPS刺激膜相关中性鞘磷脂酶(nSMase)的活性,并且这种活性对于核因子κ B (NF κ B)的释放和诱导no合成酶(iNOS)的诱导是必需的。借助新开发的选择性nSMase抑制剂C11AG,我们可以区分nSMase依赖性和非依赖性lps诱导的信号。C11AG阻断lps刺激的鞘磷脂降解和NF κ B活化,而不干扰p42酪氨酸磷酸化。同时,在单核细胞和小鼠内毒素血症中,iNOS的表达均降低。因此,nSMase的特异性抑制剂可能定义了一类新的抗炎物质。
{"title":"Neutral sphingomyelinase inhibitor C11AG prevents lipopolysaccharide-induced macrophage activation.","authors":"E Amtmann,&nbsp;W Baader,&nbsp;M Zöller","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Stimulation of macrophages by lipopolysaccharide (LPS) leads to the synthesis of proinflammatory cytokines and nitric oxide (NO) and, as a consequence, to endotoxic shock. We provide evidence that LPS stimulates the activity of a membrane-associated neutral sphingomyelinase (nSMase) and that this activity is mandatory for the liberation of nuclear factor-kappa B (NF kappa B) and the induction of inducible NO-synthase (iNOS). With the aid of a newly developed, selective inhibitor of nSMase, C11AG, we could distinguish between nSMase-dependent and -independent LPS-induced signals. C11AG blocked LPS-stimulated sphingomyelin degradation and NF kappa B activation without interfering with p42 tyrosine phosphorylation. Concomitantly, the expression of iNOS was found to be reduced both in mononuclear cells and in murine endotoxemia. Therefore, specific inhibitors of nSMase may define a new class of antiinflammatory substances.</p>","PeriodicalId":11336,"journal":{"name":"Drugs under experimental and clinical research","volume":"29 1","pages":"5-13"},"PeriodicalIF":0.0,"publicationDate":"2003-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"22486424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Drugs under experimental and clinical research
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1